A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer

Breast Cancer Research and Treatment

Volumn 151, Issue 1, 2015, Pages 27-40

  Diaby, Vakaramoko ^a   Tawk, Rima ^a   Sanogo, Vassiki ^b,c   Xiao, Hong ^d   Montero, Alberto J ^e  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b Department of Anthropology and Sociology   (Côte d’Ivoire)

^c FLORIDA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF FLORIDA HEALTH   (United States)

^e TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Chemotherapy; Cost effectiveness; Economic evaluation; Hormone therapy; Systematic review; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; HORMONE; TAXOID; VINBLASTINE; VINORELBINE TARTRATE;

ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CANCER STAGING; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HUMAN; MOLECULARLY TARGETED THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG THERAPY; FEMALE; HORMONES; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; TAXOIDS; VINBLASTINE;

EID: 84937762001     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3383-6     Document Type: Review

References (23)

1. National Cancer Institute. (2014) Cancer topics: Breast cancer. http://www.cancer.gov/cancertopics/types/breast. Accessed 5 Jan 2015. 2015:1–1
2. Benson JR, Jatoi I (2012) The global breast cancer burden. Future Oncol 8:697–702
3. Sullivan R, Peppercorn J, Sikora K et al (2011) Delivering affordable cancer care in high-income countries. Lancet Oncol 12:933–980
4. Arash R, Barfar E, Hosseini H et al (2013) Cost effectiveness of breast cancer screening using mammography; a systematic review. Iran J Public Health 42:347–357
5. Zelle SG, Baltussen RM (2013) Economic analyses of breast cancer control in low- and middle-income countries: a systematic review. Syst Rev 2:20
6. Mandelblatt J, Saha S, Teutsch S et al (2003) The cost-effectiveness of screening mammography beyond Age 65 years a systematic review for the US Preventive Services Task Force. Ann Intern Med 139:835–842
7. Okonkwo QL, Draisma G, der Kinderen A et al (2008) Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. J Natl Cancer Inst 100:1290–1300
8. Younis T, Skedgel C (2008) Is trastuzumab a cost-effective treatment for breast cancer? Expert Rev Pharmacoecon Outcomes Res 8(5):433–442
9. Becker LA, Oxman AD (2008) Overviews of reviews. In: Higgins JP (ed) Cochrane handbook for systematic reviews of interventions. Wiley, Chichester, pp 607–631
10. Smith V, Devane D, Begley CM et al (2011) Methodology in conducting a systematic review of systematic reviews of healthcare interventions. BMC Med Res Methodol 11:15
11. Canadian Agency for Drugs and Technologies in Health (2011) Grey matters: a practical search tool for evidence-based medicine. Information Services, Canadian Agency for Drugs and Technologies in Health, Ottawa
12. Shea BJ, Hamel C, Wells GA et al (2009) AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 62:1013–1020
13. Gerard K, Seymour J, Smoker I (2000) A tool to improve quality of reporting published economic analyses. Int J Technol Assess Health Care 16:100–110
14. Ferrusi IL, Leighl NB, Kulin NA et al (2011) Do economic evaluations of targeted therapy provide support for decision makers? Am J Manag Care 17(Suppl 5 Developing):SP61–SP70
15. Parkinson B, Pearson SA, Viney R (2014) Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique. Eur J Health Econ 15:93–112
16. Lewis R, Bagnall AM, King S et al (2002) The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: a systematic review and economic evaluation. Health Technol Assess 6:1–269
17. John-Baptiste AA, Wu W, Rochon P et al (2013) A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer. PLoS One 8:e62614
18. Chan AL, Leung HW, Lu CL et al (2009) Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review. Ann Pharmacother 43:296–303
19. Frederix GW, Severens JL, Hovels AM et al (2012) Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes. Value Health 15:94–105
20. Foster TS, Miller JD, Boye ME et al (2011) The economic burden of metastatic breast cancer: a systematic review of literature from developed countries. Cancer Treat Rev 37:405–415
21. Benedict A, Brown RE (2005) Review of cost-effectiveness analyses in hormonal therapies in advanced breast cancer. Expert Opin Pharmacother 6:1789–1801
22. Blank PR, Dedes KJ, Szucs TD (2010) Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review. Pharmacoeconomics 28:629–647
23. Norum J (2006) The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer. Expert Opin Pharmacother 7:1617–1625